Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00465959 · ClinicalTrials.gov registry record · Phase 1
Study of Trospium Chloride Inhalation Powder (TrIP) in Patients With Chronic Obstructive Pulmonary Disease
A Phase 1 study, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT00465959: Completed Phase 1 study, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
NCT00465959 is a Phase 1 study that has completed, run by Endo USA Inc., a Keenova Therapeutics Company. The registered enrollment target is 24 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00465959, a Phase 1 study, has completed, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
To assess the effect of a single dose of TrIP on pulmonary function in patients with COPD
Interventions
- DRUG Placebo
- DRUG trospium chloride inhalation powder (TrIP)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2007-04 |
| Est. Completion | 2007-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00465959
The ClinicalTrials.gov registry entry for NCT00465959 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Endo USA Inc., a Keenova Therapeutics Company, which has 61 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00465959 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00465959 about?
NCT00465959 is a clinical study titled "Study of Trospium Chloride Inhalation Powder (TrIP) in Patients With Chronic Obstructive Pulmonary Disease". To assess the effect of a single dose of TrIP on pulmonary function in patients with COPD
What is the current status of trial NCT00465959?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2007-04. Estimated completion is 2007-06.
What interventions are being tested in trial NCT00465959?
The interventions under investigation include: Placebo (DRUG), trospium chloride inhalation powder (TrIP) (DRUG).
Who is sponsoring clinical trial NCT00465959?
This trial is sponsored by Endo USA Inc., a Keenova Therapeutics Company, which has 61 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.